Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
BioPharmaceutical Platform Technologies

BIND Biosciences Inc.

This article was originally published in Start Up

  • Analysis

Executive Summary

BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.
Table

View full table

Advertisement

Related Content

Pink Sheet
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
Pink Sheet
FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
Scrip
Tempo Pharmaceuticals Inc.
Scrip
TransGenex Nanobiotech Inc.
Scrip
Liquidia Technologies Inc.
Scrip
Nanolymf Ltd.
In Vivo
Start-Up Previews (04/2008)
Scrip
Nanotechnology: A Balm for the Challenges of Drug Delivery
Scrip
Nanotechnology: A Balm for the Challenges of Drug Delivery
In Vivo
Start-Up Previews (04/2008)

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical Platform Technologies
UsernamePublicRestriction

Register

SC091562

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By